Corvus Pharmaceuticals, Inc. (CRVS)
The price, the headline numbers and the latest news, in one place.
Corvus Pharmaceuticals, Inc. (CRVS) Stock Price, Analysis & Data
| Bid | 10.15 |
| Market Cap | 1.18B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -54.1M |
| 0.87 | |
| -0.64 | |
| n/a | |
| -13.15 | |
| P/B (ttm) | 5.24 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 3, 2026 |
| Ask | 18.2 |
| Volume | 784,181 |
| Avg. Volume (20D) | 1,083,116 |
| Open | 14.09 |
| Previous Close | 14.16 |
| Day's Range | 13.71 - 14.16 |
| 52-Week Range | 5.58 - 26.95 |
| Analyst | n/a |
| Price Target | 32 (127.92%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of ...
Financial Performance
In 2025, Corvus Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -15.28M, a decrease of -75.47%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for CRVS stock is "null". The 12-month stock price forecast is 32, which is upside of 127.92% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.19 misses estimates by -0.02, with -46.15% YoY decline.
Analysts project revenue of ... Upgrade
